CClinicalTrials.gg
CompletedNCT02069665Updated Feb 24, 2014

Effectiveness Study of Integrative Treatment for Pediatric Pneumonia

An interventional study of Fuxiong San and Xiyanping injection in Pneumonia, sponsored by Liaoning University of Traditional Chinese Medicine. Completed at 6 sites in China. Open to participants aged 6 Months to 59 Months. Per ClinicalTrials.gov, last updated 2014-02-24.

Sponsored by Liaoning University of Traditional Chinese Medicine · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
451
Allocation
Randomized
Ages
6 Months to 59 Months
Sex
All
01

Study summary

The purpose of this study is to evaluate the effectiveness of traditional Chinese medicine for treatment of pediatric pneumonia. It is a multicenter randomized controlled trial.

Read the detailed description

The retrospective case study has been finished at the National clinical research base of traditional Chinese medicine for major disease pediatric pneumonia, and the research center organized the field training of prospective-study to coordinated units. Based on the primary statistical outcomes of retrospective case study and the discussion around prospective-study during the training, investigators found it difficult to include simplex viral infection, therefore, investigators revised the inclusion criteria and treatment protocol of the pragmatic randomized controlled trial.

The block randomization is used in this trial. Random numbers are generated by SPSS software. Statistical analysis staff and those who perform the follow-up are blinded. Sample size calculation was performed, which was 369, and considering drop-out or withdrawal, investigators plan to enroll 450 patients (300 in experimental group, 150 in control).

02

Conditions studied

  • Pneumonia

Browse trials for

Keywords

  • pneumonia
  • pediatrics
  • viral
03

In context

Pneumonia

2,044 studies on the registry are indexed under Pneumonia; 283 are open to participants now.

This study's enrollment of 451 is above the median of 106 across 1,247 interventional studies indexed under Pneumonia.

Browse Pneumonia studies →

Lead sponsor

Liaoning University of Traditional Chinese Medicine is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 59 Months
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • children, aged 6 months to 59 months old, diagnosed as pneumonia according to western medicine diagnostic criteria;
  • diagnosed as TCM pneumonia with gasp-cough, meeting wind-heat blocking lungs pattern (feng re bi fei zheng), and phlegm-heat blocking lungs pattern (tan re bi fei zheng);
  • disease progression within 72 hours;
  • those whose guardians understood and assigned the informed consent;

Exclusion criteria

Exclusion Criteria:

  • emergency pneumonia;
  • complicated with other Pulmonary Disorders attack other than pneumonia;
  • complicated with primary disease of heart (congenital heart disease, myocarditis, et al), liver (ALT, and AST ≥ 1.5 times of normal value ceiling), kidney (BUN > 8.2mmol/L, or serum CR > 104 µmol/L, et al) and blood system (anemia), and those with psychopathy;
  • allergic to interventional medications;
  • those who are participating or have participated in other clinical trials in 3 months.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
451 participants (actual)

Study arms

  • Experimental
    Injection, medications and application

    Intravenous injection: Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co., Ltd; Medications: according to TCM syndrome differentiations; * Wind-heat blocking lungs pattern (feng re bi fei zheng): Xiaoer Qingfei Heji (mixture), and Zhi Ke San (herbal powder to relieve cough) * Phlegm-heat blocking lungs pattern (tan re bi fei zheng): Xiaoer Qingfei Heji (mixture), and Hua Tan San (herbal powder to remove phlegm) External application: Fuxiong San

    Other: Fuxiong San · Drug: Xiyanping injection · Drug: Xiaoer Qingfei Heji (mixture) · Drug: Zhi Ke San · Drug: Hua Tan San

  • Active comparator
    Injection and medications

    Intravenous injection: Ribavirin Injection; Medications: symptomatic therapies * Guaifenesin Syrup, for removing phlegm, relieving gasp-cough; * Ibuprofen Suspension, and salbutamol in case of different symptoms

    Drug: Ribavirin Injection · Drug: Guaifenesin Syrup · Drug: Ibuprofen Suspension · Drug: salbutamol

Interventions

  • OtherFuxiong San

    external application; 8-10cm wide, 0.3-0.5cm thick; 10mins for patient aged 1 to 3-year old; 15mins for those aged 3 to 5-year old; once daily

  • DrugXiyanping injection

    ivd. 5 to 10 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection.

  • DrugRibavirin Injection

    ivd. 10 to 20 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection.

  • DrugXiaoer Qingfei Heji (mixture)

    children aged 6 months to 1 year old: 10 ml, orally taken three times daily; children aged 1 to 3 year old: 15 ml, orally taken three times daily; children aged 3 to 5 year old: 20 ml, orally taken three times daily;

  • DrugZhi Ke San

    children aged 6 months to 1 year old: 0.5g, orally taken three times daily; children aged 1 to 3 year old: 1.5g, orally taken three times daily; children aged 3 to 5 year old: 2.0g, orally taken three times daily;

    Also known as: herbal powder to relieve cough

  • DrugHua Tan San

    children aged 6 months to 1 year old: 0.5g, orally taken three times daily; children aged 1 to 3 year old: 1.5g, orally taken three times daily; children aged 3 to 5 year old: 2.0g, orally taken three times daily;

    Also known as: herbal powder to remove phlegm

  • DrugGuaifenesin Syrup

    children aged 6 months to 1 year old: 3ml, orally taken three times daily; children aged 1 to 3 year old: 5ml, orally taken three times daily; children aged 3 to 5 year old: 8ml, orally taken three times daily;

    Also known as: Guaifenesin, Methylephedrine and Chlorphenamine Syrup

  • DrugIbuprofen Suspension

    taken under prescription

    Also known as: Motrin

  • Drugsalbutamol

    taken under prescription

    Also known as: β2-agonists

06

What researchers measure

Primary outcomes

  1. Cured rate

    Clinical symptoms and signs totally disappear, the period of lab tests return to normal is recorded.

    Time frame: Every day since receiving treatment, all together 10 days (times)

  2. Effectiveness time window

    days range from treatment is received to the effectiveness is observed, and symptoms disappear

    Time frame: Every day since receiving treatment, all together 10 days (times)

Secondary outcomes

  1. TCM syndrome scores and effective rate

    Total effective rate according to TCM syndrome differentiation and treatment, and single syndrome effective rate

    Time frame: 10 days

  2. Effect in fever, cough, phlegm and gasp

    temperature, fever frequency, fever lasting time, Ibuprofen Suspension dosing; cough severity; phlegm amount, color and nature; gasp frequency, severity, all to be measured

    Time frame: 10 days

  3. Time of lung rales disappear completely

    days are counted since receiving treatment, when the chest radiograph returns to normal

    Time frame: 10 days

  4. Check-out time

    days counted when the patient checks out

    Time frame: 10 days

  5. Pulmonary disease incidence

    unresolved pneumonia, chronic cough, cough variant asthma incidence in the follow-up

    Time frame: 30 days

Other outcomes

  1. Direct medical cost

    Medical cost including hospital expenses, examine fee, medication fee, et al, related to treatment in hospital

    Time frame: observed during treatment in 10 days

07

Study locations

6 sites
  • Affiliated Children's Hospital of Capital University of Medical Sciences
    Beijing, Beijing 100045, China
  • Guangzhou Children's Hospital
    Guangzhou, Guangdong 510120, China
  • Affiliated Children's Hospital of Dalian Medical University
    Dalian, Liaoning 116044, China
  • Affiliated Hospital of Liaoning University of TCM
    Shenyang, Liaoning 110032, China
  • Affiliated Hospital of Shandong University of TCM
    Ji'nan, Shandong 250011, China
  • Affiliated Longhua Hospital of Shanghai University of TCM
    Shanghai, Shanghai 200032, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 24, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02069665
Lead sponsor
Liaoning University of Traditional Chinese Medicine
Collaborators
Beijing University of Chinese Medicine
Responsible party
Xuefeng Wang (Chief physician, Liaoning University of Traditional Chinese Medicine) — Principal investigator
First posted
Feb 24, 2014
Start date
Dec 2011
Primary completion
Jul 2013
Completion
Aug 2013
Last update
Feb 24, 2014

Study contacts

Xuefeng Wang, Ph.D.
study director · Affiliated Hospital of Liaoning University of TCM
Zhenqi Wu
principal investigator · Affiliated Hospital of Liaoning University of TCM

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion